Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder.
Pharmacogenomics
; 21(2): 111-123, 2020 01.
Article
en En
| MEDLINE
| ID: mdl-31957548
ABSTRACT
Introduction:
Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials &methods:
Patients (175 males, average age 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction.Results:
The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001.Conclusion:
This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trastornos de Ansiedad
/
Benzodiazepinas
/
Alcoholismo
/
Citocromo P-450 CYP2C19
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pharmacogenomics
Asunto de la revista:
FARMACOLOGIA
/
GENETICA MEDICA
Año:
2020
Tipo del documento:
Article